1	Effects	Effect	B-NP	NNS	O	0	ROOT	16	Effects
2	of	of	B-PP	IN	O	1	NMOD	-1
3	spironolactone	spironolactone	B-NP	NN	O	2	PMOD	-1
4	on	on	B-PP	IN	O	1	NMOD	-1
5	corneal	corneal	B-NP	JJ	O	7	NMOD	-1
6	allograft	allograft	I-NP	NN	O	7	NMOD	-1
7	survival	survival	I-NP	NN	O	4	PMOD	5	survival
8	in	in	B-PP	IN	O	7	NMOD	-1
9	the	the	B-NP	DT	O	10	NMOD	-1
10	rat	rat	I-NP	NN	O	8	PMOD	-1
11	.	.	O	.	O	1	P	-1

1	PURPOSE	PURPOSE	B-NP	NN	O	3	NMOD	-1
2	:	:	O	:	O	1	P	-1
3	Spironolactone	Spironolactone	B-NP	NN	O	4	SUB	-1
4	has	have	B-VP	VBZ	O	0	ROOT	-1
5	recently	recently	I-VP	RB	O	4	VMOD	-1
6	been	be	I-VP	VBN	O	4	VC	-1
7	shown	show	I-VP	VBN	O	6	VC	-1
8	to	to	I-VP	TO	O	9	VMOD	-1
9	have	have	I-VP	VB	O	7	VMOD	-1
10	suppressive	suppressive	B-NP	JJ	O	11	NMOD	-1
11	effects	effect	I-NP	NNS	O	9	OBJ	0
12	on	on	B-PP	IN	O	9	VMOD	-1
13	several	several	B-NP	JJ	O	12	PMOD	-1
14	immunoactive	immunoactive	I-NP	JJ	O	13	NMOD	-1
15	and	and	I-NP	CC	O	13	NMOD	-1
16	proinflammatory	proinflammatory	I-NP	JJ	B-protein	13	NMOD	-1
17	cytokines	cytokine	I-NP	NNS	I-protein	13	NMOD	-1
18	.	.	O	.	O	4	P	-1

1	In	In	B-PP	IN	O	6	VMOD	-1
2	this	this	B-NP	DT	O	3	NMOD	-1
3	study	study	I-NP	NN	O	1	PMOD	-1
4	,	,	O	,	O	6	P	-1
5	we	we	B-NP	PRP	O	6	SUB	-1
6	investigated	investigate	B-VP	VBD	O	0	ROOT	-1
7	the	the	B-NP	DT	O	8	NMOD	-1
8	effects	effect	I-NP	NNS	O	6	OBJ	16	effects
9	of	of	B-PP	IN	O	8	NMOD	-1
10	spironolactone	spironolactone	B-NP	NN	O	9	PMOD	-1
11	on	on	B-PP	IN	O	8	NMOD	-1
12	the	the	B-NP	DT	O	13	NMOD	-1
13	prevention	prevention	I-NP	NN	O	11	PMOD	18	prevention
14	of	of	B-PP	IN	O	13	NMOD	-1
15	corneal	corneal	B-NP	JJ	O	17	NMOD	-1
16	allograft	allograft	I-NP	NN	O	17	NMOD	-1
17	rejection	rejection	I-NP	NN	O	14	PMOD	5	rejection
18	in	in	B-PP	IN	O	17	NMOD	-1
19	a	a	B-NP	DT	O	27	NMOD	-1
20	MHC	MHC	I-NP	NN	B-cell_line	27	NMOD	-1
21	class	class	I-NP	NN	I-cell_line	27	NMOD	-1
22	I/II	I/II	I-NP	NN	I-cell_line	27	NMOD	-1
23	mismatch	mismatch	I-NP	NN	I-cell_line	27	NMOD	-1
24	rat	rat	I-NP	NN	I-cell_line	27	NMOD	-1
25	corneal	corneal	I-NP	NN	I-cell_line	27	NMOD	-1
26	transplant	transplant	I-NP	NN	I-cell_line	27	NMOD	19	transplant
27	model	model	I-NP	NN	I-cell_line	18	PMOD	-1
28	.	.	O	.	O	6	P	-1

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT	-1
2	:	:	O	:	O	1	P	-1
3	Grafted	Graft	B-NP	VBN	O	4	NMOD	0
4	animals	animal	I-NP	NNS	O	9	SUB	-1
5	for	for	B-PP	IN	O	4	NMOD	-1
6	corneal	corneal	B-NP	JJ	O	8	NMOD	-1
7	survival	survival	I-NP	NN	O	8	NMOD	5	survival
8	analysis	analysis	I-NP	NN	O	5	PMOD	-1
9	were	be	B-VP	VBD	O	1	NMOD	-1
10	assigned	assign	I-VP	VBN	O	9	VC	-1
11	to	to	I-VP	TO	O	12	VMOD	-1
12	receive	receive	I-VP	VB	O	10	VMOD	-1
13	either	either	O	CC	O	15	NMOD	-1
14	spironolactone	spironolactone	B-NP	NN	O	15	NMOD	-1
15	suspension	suspension	I-NP	NN	O	12	OBJ	-1
16	(	(	O	(	O	12	VMOD	-1
17	orally	orally	B-ADVP	RB	O	12	VMOD	-1
18	,	,	O	,	O	12	P	-1
19	100	100	B-NP	CD	O	20	NMOD	-1
20	mg/kg/day	mg/kg/day	I-NP	NN	O	24	NMOD	-1
21	,	,	O	,	O	24	P	-1
22	n	n	B-NP	NN	O	24	SUB	-1
23	=	=	B-VP	SYM	O	24	VMOD	-1
24	7	7	B-NP	CD	O	12	VMOD	-1
25	)	)	O	)	O	24	NMOD	-1
26	,	,	O	,	O	12	P	-1
27	phosphate-buffered	phosphate-buffered	B-NP	JJ	O	28	NMOD	-1
28	saline	saline	I-NP	NN	O	12	OBJ	-1
29	(	(	O	(	O	28	NMOD	-1
30	PBS	PBS	B-NP	NNS	O	29	ROOT	-1
31	,	,	O	,	O	30	P	-1
32	orally	orally	B-ADVP	RB	O	30	NMOD	-1
33	,	,	O	,	O	32	P	-1
34	same	same	B-NP	JJ	O	35	NMOD	-1
35	volume	volume	I-NP	NN	O	39	NMOD	-1
36	as	as	B-PP	IN	O	35	NMOD	-1
37	spironolactone	spironolactone	B-NP	NN	O	36	PMOD	-1
38	,	,	O	,	O	39	P	-1
39	n	n	B-NP	NN	O	33	NMOD	-1
40	=	=	B-VP	SYM	O	39	NMOD	-1
41	9	9	B-NP	CD	O	40	AMOD	-1
42	)	)	O	)	O	39	NMOD	-1
43	or	or	O	CC	O	39	NMOD	-1
44	remained	remain	B-VP	VBD	O	43	DEP	-1
45	untreated	untreated	B-ADJP	JJ	O	44	PRD	0
46	(	(	O	(	O	50	DEP	-1
47	n	n	B-NP	NN	O	50	DEP	-1
48	=	=	B-VP	SYM	O	47	NMOD	-1
49	16	16	B-NP	CD	O	48	AMOD	-1
50	)	)	O	)	O	45	AMOD	-1
51	.	.	O	.	O	39	P	-1

1	Additional	Additional	B-NP	JJ	O	3	NMOD	-1
2	grafted	grafted	I-NP	JJ	O	3	NMOD	19	grafted
3	rats	rat	I-NP	NNS	O	19	SUB	-1
4	treated	treat	B-VP	VBN	O	3	NMOD	19	treated
5	with	with	B-PP	IN	O	4	VMOD	-1
6	spironolactone	spironolactone	B-NP	NN	O	13	NMOD	-1
7	(	(	O	(	O	11	DEP	-1
8	n	n	B-NP	NN	O	10	SUB	-1
9	=	=	B-VP	SYM	O	10	VMOD	-1
10	6	6	B-NP	CD	O	11	DEP	-1
11	)	)	O	)	O	6	NMOD	-1
12	or	or	O	CC	O	13	NMOD	-1
13	PBS	PBS	B-NP	NNS	B-protein	5	PMOD	-1
14	(	(	O	(	O	18	DEP	-1
15	n	n	B-NP	NN	O	17	SUB	-1
16	=	=	B-VP	SYM	O	17	VMOD	-1
17	8	8	B-NP	CD	O	18	DEP	-1
18	)	)	O	)	O	13	NMOD	-1
19	were	be	B-VP	VBD	O	0	ROOT	-1
20	sacrificed	sacrifice	I-VP	VBN	O	19	VC	19	sacrificed
21	on	on	B-PP	IN	O	20	VMOD	-1
22	day	day	B-NP	NN	O	21	PMOD	-1
23	12	12	I-NP	CD	O	22	NMOD	-1
24	for	for	B-PP	IN	O	20	VMOD	-1
25	quantitative	quantitative	B-NP	JJ	O	27	NMOD	-1
26	RT-PCR	RT-PCR	I-NP	NN	O	27	NMOD	-1
27	analysis	analysis	I-NP	NN	O	24	PMOD	-1
28	for	for	B-PP	IN	O	27	NMOD	-1
29	mechanistic	mechanistic	B-NP	JJ	O	30	NMOD	-1
30	studies	study	I-NP	NNS	O	28	PMOD	-1
31	.	.	O	.	O	19	P	-1

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT	0
2	:	:	O	:	O	1	P	-1
3	Mean	Mean	B-NP	NN	O	8	NMOD	-1
4	(	(	O	(	O	6	DEP	-1
5	+/-SEM	+/-SEM	B-NP	NN	O	6	DEP	-1
6	)	)	O	)	O	3	NMOD	-1
7	graft	graft	B-NP	NN	O	8	NMOD	-1
8	survival	survival	I-NP	NN	O	9	SUB	5	survival
9	was	be	B-VP	VBD	O	1	NMOD	-1
10	significantly	significantly	I-VP	RB	O	9	VMOD	-1
11	prolonged	prolong	I-VP	VBN	O	9	VC	17	prolonged
12	in	in	B-PP	IN	O	11	VMOD	-1
13	animals	animal	B-NP	NNS	O	12	PMOD	-1
14	receiving	receive	B-VP	VBG	O	13	NMOD	19	receiving
15	spironolactone	spironolactone	B-NP	NN	O	14	OBJ	-1
16	(	(	O	(	O	21	DEP	-1
17	14.9	14.9	B-NP	CD	O	19	AMOD	-1
18	+/-	+/-	I-NP	CC	O	19	AMOD	-1
19	2.0	2.0	I-NP	CD	O	20	NMOD	-1
20	days	day	I-NP	NNS	O	21	DEP	-1
21	)	)	O	)	O	15	NMOD	-1
22	compared	compare	B-PP	VBN	O	11	VMOD	-1
23	with	with	B-PP	IN	O	22	PMOD	-1
24	both	both	O	CC	O	38	NMOD	-1
25	PBS-treated	PBS-treated	O	JJ	O	38	NMOD	19	treated
26	(	(	O	(	O	35	DEP	-1
27	12.3	12.3	B-NP	CD	O	29	AMOD	-1
28	+/-	+/-	I-NP	CC	O	29	AMOD	-1
29	1.2	1.2	I-NP	CD	O	30	NMOD	-1
30	days	day	I-NP	NNS	O	34	NMOD	-1
31	,	,	O	,	O	34	P	-1
32	p	p	B-NP	NN	O	34	SUB	-1
33	=	=	B-VP	SYM	O	34	VMOD	-1
34	0.007	0.007	B-NP	CD	O	35	DEP	-1
35	)	)	O	)	O	25	AMOD	-1
36	and	and	O	CC	O	38	NMOD	-1
37	untreated	untreated	B-NP	JJ	O	38	NMOD	19	untreated
38	controls	control	I-NP	NNS	O	23	PMOD	0
39	(	(	O	(	O	48	DEP	-1
40	13.0	13.0	B-NP	CD	O	42	AMOD	-1
41	+/-	+/-	I-NP	CC	O	42	AMOD	-1
42	1.0	1.0	I-NP	CD	O	43	NMOD	-1
43	days	day	I-NP	NNS	O	48	DEP	-1
44	,	,	O	,	O	48	P	-1
45	p	p	B-NP	NN	O	48	DEP	-1
46	=	=	B-VP	SYM	O	45	NMOD	-1
47	0.01	0.01	B-NP	CD	O	46	AMOD	-1
48	)	)	O	)	O	38	NMOD	-1
49	.	.	O	.	O	1	P	-1

1	We	We	B-NP	PRP	O	2	SUB	-1
2	found	find	B-VP	VBD	O	0	ROOT	0
3	a	a	B-NP	DT	O	4	NMOD	-1
4	decrease	decrease	I-NP	NN	O	2	OBJ	18	decrease
5	in	in	B-PP	IN	O	4	NMOD	-1
6	corneal	corneal	B-NP	JJ	O	7	NMOD	-1
7	neovascularization	neovascularization	I-NP	NN	O	5	PMOD	3	neovascularization
8	in	in	B-PP	IN	O	4	NMOD	-1
9	spironolactone-treated	spironolactone-treated	B-NP	JJ	O	10	NMOD	19	treated
10	rats	rat	I-NP	NNS	O	8	PMOD	-1
11	compared	compare	B-PP	VBN	O	4	NMOD	-1
12	with	with	B-PP	IN	O	11	VMOD	-1
13	the	the	B-NP	DT	O	15	NMOD	-1
14	PBS-treated	PBS-treated	I-NP	JJ	O	15	NMOD	19	treated
15	group	group	I-NP	NN	O	12	PMOD	-1
16	,	,	O	,	O	2	P	-1
17	although	although	B-SBAR	IN	O	2	VMOD	-1
18	the	the	B-NP	DT	O	19	NMOD	-1
19	difference	difference	I-NP	NN	O	20	SUB	-1
20	was	be	B-VP	VBD	O	17	SBAR	-1
21	not	not	O	RB	O	20	VMOD	-1
22	statistically	statistically	B-ADJP	RB	O	20	VMOD	-1
23	significant	significant	I-ADJP	JJ	O	20	PRD	-1
24	.	.	O	.	O	2	P	-1

1	Spironolactone	Spironolactone	B-NP	NN	O	2	SUB	-1
2	affected	affect	B-VP	VBD	O	0	ROOT	16	affected
3	both	both	O	CC	O	16	NMOD	-1
4	systemic	systemic	O	JJ	O	16	NMOD	-1
5	(	(	O	(	O	12	DEP	-1
6	down-regulation	down-regulation	B-NP	NN	O	12	DEP	18	down-regulation
7	of	of	B-PP	IN	O	6	NMOD	-1
8	CD25+	CD25+	B-NP	JJ	B-cell_type	9	NMOD	-1
9	cells	cell	I-NP	NNS	I-cell_type	7	PMOD	-1
10	in	in	B-PP	IN	O	6	NMOD	-1
11	spleen	spleen	B-NP	NN	O	10	PMOD	-1
12	)	)	O	)	O	4	NMOD	-1
13	and	and	O	CC	O	16	NMOD	-1
14	local	local	B-NP	JJ	O	16	NMOD	-1
15	immune	immune	I-NP	JJ	O	16	NMOD	-1
16	response	response	I-NP	NN	O	2	OBJ	0
17	(	(	O	(	O	23	DEP	-1
18	up-regulation	up-regulation	B-NP	NN	O	23	DEP	17	up-regulation
19	of	of	B-PP	IN	O	18	NMOD	-1
20	IL-10	IL-10	B-NP	NN	B-protein	19	PMOD	-1
21	in	in	B-PP	IN	O	18	NMOD	-1
22	cornea	cornea	B-NP	NN	O	21	PMOD	-1
23	)	)	O	)	O	16	NMOD	-1
24	.	.	O	.	O	2	P	-1

1	CONCLUSION	CONCLUSION	B-NP	NN	O	4	VMOD	-1
2	:	:	O	:	O	4	P	-1
3	We	We	B-NP	PRP	O	4	SUB	-1
4	present	present	B-VP	VBP	O	0	ROOT	0
5	initial	initial	B-NP	JJ	O	6	NMOD	-1
6	results	result	I-NP	NNS	O	4	OBJ	0
7	demonstrating	demonstrate	B-VP	VBG	O	6	NMOD	-1
8	anti-inflammatory	anti-inflammatory	B-NP	JJ	O	9	NMOD	-1
9	effects	effect	I-NP	NNS	O	7	OBJ	0
10	of	of	B-PP	IN	O	9	NMOD	-1
11	spironolactone	spironolactone	B-NP	NN	O	10	PMOD	-1
12	.	.	O	.	O	4	P	-1

